September 16, 2022 News by Marisa Wexler, MS NurOwn Found Safe, Shows Promise in Phase 2 Trial for Progressive MS NurOwn, a stem cell therapy being developed by BrainStorm Cell Therapeutics, showed a good safety profile among people with progressive forms of multiple sclerosis (MS) in an open-label Phase 2 clinical trial, according to new data. The data show the experimental therapy also was associated with promising effects on…
June 18, 2021 News by Marta Figueiredo, PhD Brainstorm Secures NurOwn-associated Patents in Several Markets In the past year, BrainStorm Cell Therapeutics was granted four patents and is waiting for a fifth, already accepted, meant to provide protection for its NurOwn cell therapy and technology in territories around the world. NurOwn is being tested in clinical trials as a potential treatment for…
March 26, 2021 News by Vanda Pinto, PhD NurOwn Cell Therapy Found Safe, Effective for Progressive MS in Phase 2 Trial NurOwn cell therapy led to significant improvements in the physical abilities, vision, and cognition of people withĀ progressive multiple sclerosis (MS) in a Phase 2 clinical trial, top-line data show. In addition to these positive efficacy results, BrainStorm Cell Therapeutics, NurOwn’s developer, announced that its cell-based therapy showed…
December 21, 2020 News by Marta Figueiredo, PhD Dosing Finishes in Trial of NurOwn Cell Therapy for Progressive MS Patient dosing has finished in a Phase 2 clinical trial testingĀ NurOwn, BrainStorm Cell Therapeuticsā investigational cell-based therapy for people with progressive multiple sclerosis (MS), the company announced. The trialās top-line results are…
August 27, 2020 News by Joana Carvalho, PhD #MSVirtual2020 – MRI Changes Can Reflect Function in Progressive MS, Study Says Certain MRI measures of the brain and spinal cord directly associate with functional improvements in people with progressive multiple sclerosis (MS), a new study reports. According to BrainStorm Cell Therapeutics, these data will help in determining the benefits ofĀ NurOwn, the companyās stem cell-based…
May 11, 2020 Columns by Ed Tobias MS News that Caught My Eye Last Week: Bafiertam, Stem Cell Transplant Damage, Gilenya Study, NurOwn Benefits FDA Approves Bafiertam, Tecfidera Bioequivalent, for Relapsing MS This is the second disease-modifying therapy (DMT) OK’d by the FDA in the past few months. Bafiertam is a delayed-release pill that’s similar to Tecfidera, but it’s said that it has fewer side effects. Unfortunately, its manufacturer hasn’t yet made it…
May 7, 2020 News by InĆŖs Martins, PhD NurOwn May Curb Damaging Neuroinflammation in MS, Study Finds NurOwn, believed to haveĀ neuroprotective and repairing effects,Ā may also be able to curb the damaging immune responses that contribute to multiple sclerosis (MS) progression, a recent study found. This newly identified potential may extend the benefits of this cell-based therapy, its researchers believe. The findings were to be presented…
March 16, 2020 Columns by Ed Tobias MS News that Caught My Eye Last Week: Coronavirus Updates, MD1003 Trial Fails to Meet Goals, Sativex and Spasticity Relief, NurOwn Trial Site Announced Second Phase 3 Trial of MedDayās MD1003 for Progressive MS Fails to Meet Goals This is disappointing news about what scientists had hoped would be another oral disease-modifying therapy for multiple sclerosis. It’s doubly disappointing because MD1003 is aimed at progressive forms of MS and demyelination, and we need…
March 9, 2020 News by Catarina Silva Final Site Announced in Phase 2 Trial Testing NurOwn in Progressive MS The Partners Multiple Sclerosis Center at Brigham and Womenās Hospital has joined BrainStorm Cell Therapeutics in a Phase 2 trial exploring the safety and efficacy of NurOwn in the treatment of progressive multiple sclerosis (MS). This is the fifth and final clinical site participating in…
December 18, 2019 News by Mary Chapman BrainStorm Cell Therapeutics Wins 2020 āBuzz of BIOā Award For its promising investigational therapeutic approach to neurodegenerative diseases, including progressive multiple sclerosis (MS), BrainStorm Cell Therapeutics is theĀ Buzz of BIO 2020 winnerĀ in the Public Therapeutic Biotech category. The Buzz of BIO contest identifies U.S. companies with groundbreaking, early-stage potential to improve lives. The…
December 2, 2019 News by Alice MelĆ£o, MSc Mount Sinai Taking Part in Phase 2 Trial of NurOwn Cell Therapy in Progressive MS Mount Sinai Medical Center has joined withĀ BrainStorm Cell Therapeutics to explore the safety and efficacy of NurOwn as a potential treatment for progressive multiple sclerosis (MS) in an ongoing Phase 2 trial. The New York center is the fourth clinical site participating in the trial, in addition…
November 19, 2019 News by Iqra Mumal, MSc NMSS Awards $495K to Study Biomarkers in Phase 2 Trial of NurOwn in Progressive MS BrainStorm Cell TherapeuticsĀ received a $495,330 grant from the National Multiple Sclerosis (MS) SocietyĀ to support biomarker studies in its ongoing clinical trial testing the cell therapyĀ NurOwn in patients with progressive multiple sclerosis (MS). NurOwn is a treatment based on the patientsā own bone marrow-derivedĀ mesenchymal stem…
July 12, 2019 News by Patricia Inacio, PhD Phase 2 Trial Testing NurOwn Therapy for Progressive MS Adds Third Clinical Site The Phase 2 clinical trial testing BrainStorm Cell Therapeuticās investigationalĀ NurOwnĀ therapy for progressive multiple sclerosis (MS) has added a third clinical site, the company announced. The trial (NCT03799718) now will enroll patients at the Keck School of MedicineĀ ofĀ The University of Southern California (USC), and its academic…
March 18, 2019 News by Jonathan Grinstein Progressive MS Phase 2 Trial of NurOwn Stem Cell Therapy Enrolls 1st Patient The first patient has been enrolled in a Phase 2 multicenter clinical trial testing the use of NurOwn cellular therapy to treat progressive multiple sclerosis (MS), BrainStorm Cell Therapeutics announced. The open-label trialĀ (NCT03799718), titled Safety and Efficacy of Repeated Administration ofĀ neuronĀ (MSC-NTF Cells) nin Participants…
February 26, 2019 News by Santiago Gisler Cleveland Clinic Chosen for Phase 2 Trial Testing NurOwn Stem Cell Therapy in Progressive MS Patients BrainStorm Cell Therapeutics announced theĀ Cleveland ClinicĀ is the first clinical site contracted in the United States for the Phase 2 multi-center study evaluating the companyās NurOwn mesenchymal stem cell (MSC) therapy in individuals with progressive multiple sclerosis (MS). āWe are very excited to announce The Mellen Center for…
January 14, 2019 Columns by Ed Tobias MS News that Caught My Eye Last Week: Stimulator for Spasticity, Tysabri Dosing Trial, Mobility Devices Contest, Stem Cell Phase 2 Trial WeHealth, PathMaker Collaborating to Develop MyoRegulator as Noninvasive Treatment for Spasticity I’m one of the many people with multiple sclerosis (MS) for whom spasticity is a significant problem. This is a nonmedicinal approach to dealing with it. I hope it doesn’t take too long to make this…
January 9, 2019 News by Jonathan Grinstein BrainStorm Expands Production of Autologous Stem Cell Therapy NurOwn for Phase 2 Trial in Multiple Sclerosis BrainStorm Cell TherapeuticsĀ announced that the production of its therapyĀ NurOwn will be expanded to support upcoming clinical trials, namely a Phase 3 trial in amyotrophic lateral sclerosis (ALS) and a Phase 2 trial in progressive multiple sclerosis (MS). BrainStormās proprietary, stem cell-based technology called…
December 19, 2018 News by Alberto Molano, PhD FDA Gives Green Light to Phase 2 Trial of NurOwn Stem Cell Therapy in Progressive MS Patients The U.S. Food and Drug Administration (FDA) has approvedĀ BrainStorm Cell Therapeutics‘ request to open a Phase 2 clinical trial testing the safety and effectiveness of its proprietary NurOwn mesenchymal stem cell (MSC)Ā treatment inĀ progressive multiple sclerosis (MS) patients. The request was in the form of Investigational New Drug…
November 21, 2018 News by Alice MelĆ£o, MSc Phase 2 Trial of NurOwn Stem Cell Therapy in Progressive MS Planned for US, BrainStorm Announces BrainStorm Cell Therapeutics is planning to launch a Phase 2 clinical trial in the United States to evaluate the safety and activity of its lead cell therapy candidate,Ā NurOwn, in people with progressive multiple sclerosis (MS). The company announced that has submitted an Investigational New Drug (IND) application to…